Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Discovery and verification of osteopontin and beta-2-microglobulin as promising markers for staging human African trypanosomiasis

DSpace/Manakin Repository

Show simple item record Tiberti, N. Hainard, A. Lejon, V. Robin, X. Mumba Ngoyi, D. Turck, N. Matovu, E. Enyaru, J. Mathu Ndung, U. J. Scherl, A. Dayon, L. Sanchez, J. C. 2010-12-17T10:02:09Z 2010-12-17T10:02:09Z 2010
dc.identifier.issn 1535-9476
dc.identifier.issn UPD28
dc.identifier.other ITG-P3A
dc.identifier.other PARAS
dc.identifier.other U-SEROL
dc.identifier.other JIF
dc.identifier.other DOI
dc.identifier.other Abstract
dc.description.abstract Human African trypanosomiasis (HAT), or sleeping sickness, is a parasitic disease endemic in sub-Saharan Africa, transmitted to humans through the bite of a tsetse fly. The first or haemolymphatic stage of the disease (S1) is associated with presence of parasites in the bloodstream, lymphatic system and body tissues. If patients are left untreated, parasites cross the blood-brain barrier (BBB) and invade the cerebrospinal fluid (CSF) and the brain parenchyma, giving rise to the second or meningoencephalitic stage (S2). Stage determination is a crucial step in guiding the choice of treatment, as drugs used for S2 are potentially dangerous. Current staging methods, based on counting white blood cells (WBC) and demonstrating trypanosomes in CSF, lack specificity and/or sensitivity. In the present study, we used a number of proteomic strategies to discover new markers with potential for staging HAT. CSF samples were collected from patients infected with Trypanosoma brucei gambiense in the Democratic Republic of Congo. The stage was determined following the guidelines of the national control program. The proteome of the samples was analysed by two-dimensional gel electrophoresis (n=9), and by sixplex tandem mass tag (TMT) isobaric labeling (n=6) quantitative mass spectrometry. Overall, 73 proteins were over-expressed in patients presenting the second stage of disease. Two of these, osteopontin and beta-2-microglobulin, were confirmed to be potential markers for staging HAT by Western blot and ELISA. The two proteins significantly discriminated between S1 and S2 patients with high sensitivity (68% and 78%, respectively) for 100% specificity, and a combination of both improved the sensitivity to 91%. The levels of osteopontin and beta-2-microglobulin in CSF of S2 patients (microg/ml range), as well as the fold increased concentration in S2 compared to S1 (3.8 and 5.5 respectively) make the two markers good candidates for the development of a test for staging HAT patients en
dc.language English en
dc.subject Protozoal diseases en
dc.subject Trypanosomiasis, African en
dc.subject Sleeping sickness en
dc.subject Trypanosoma brucei gambiense en
dc.subject Vectors en
dc.subject Glossina en
dc.subject Tsetse flies en
dc.subject National programs en
dc.subject Control programs en
dc.subject Stage determination en
dc.subject Disease progression en
dc.subject Markers en
dc.subject Osteopontin en
dc.subject Beta-2-microglobulin en
dc.subject Proteomics en
dc.subject Electrophoresis en
dc.subject Congo-Kinshasa en
dc.subject Africa, Central en
dc.title Discovery and verification of osteopontin and beta-2-microglobulin as promising markers for staging human African trypanosomiasis en
dc.type Article en
dc.citation.issue 12 en
dc.citation.jtitle Molecular and Cellular Proteomics en
dc.citation.volume 9 en
dc.citation.pages 2783-2795 en
dc.citation.jabbreviation Mol Cell Proteomics en

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record